COVID-19 Emergency and Post-Emergency in Italian Cancer Patients: How Can Patients Be Assisted?
COVID-19
cancer patients
coronavirus
infections
telemedicine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
05
2020
accepted:
21
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Italy and worldwide are experiencing an outbreak of a new coronavirus-related disease, named COVID-19, declared by the WHO COVID-19 a pandemic. The fragility of cancer patients is well-known, with many cases affecting aged patients or those with several comorbidities that frequently result in a loss of independency and functionality. Therefore, cancer patients have been greatly affected by this health emergency and, due to their vulnerability to COVID-19, oncologic patient visits have been often delayed or canceled leading to possible under-treatment. Different solutions can be adopted for reducing travels to cancer screening centers and the overall impact of cancer screening visits. As a consequence, it has been recommended that, when possible, the follow-up visits for cancer patients treated with oral anticancer drugs could be performed telematically. Furthermore, many patients refuse hospital visits, even if necessary, because of fear of contagion. Moreover, in some regions in Italy even the very first non-urgent visits have been postponed with the consequent delay in diagnosis, which may negatively affect disease prognosis. For these reasons, new approaches are needed such as the telemedicine tool. Throughout organized and appropriate tools, it would be possible to manage patients' visits and treatments, to avoid the dangerous extension of waiting lists when the standard activities will resume. In this context, a number of hospital visits can be substituted with visits at small local health centers, and general practitioners'office, taking in turn, advantage of well-defined telemedicine path which will be developed in the post-emergency phase.
Identifiants
pubmed: 32850461
doi: 10.3389/fonc.2020.01571
pmc: PMC7431560
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1571Informations de copyright
Copyright © 2020 Crispo, Montagnese, Perri, Grimaldi, Bimonte, Augustin, Amore, Celentano, Di Napoli, Cascella and Pignata.
Références
J Med Internet Res. 2017 Jan 09;19(1):e11
pubmed: 28069561
Biosci Rep. 2019 Jan 18;39(1):
pubmed: 30530866
JCO Glob Oncol. 2020 Mar;6:471-475
pubmed: 32196389
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Ann Ist Super Sanita. 2016 Jul-Sep;52(3):434-442
pubmed: 27698303
BMC Med. 2017 Jun 19;15(1):119
pubmed: 28625164
Thorac Cancer. 2020 Jun;11(6):1752-1757
pubmed: 32291968
Cochrane Database Syst Rev. 2015 Sep 07;(9):CD002098
pubmed: 26343551
J Telemed Telecare. 2005;11(1):3-9
pubmed: 15829036
BMJ Open. 2017 Aug 3;7(8):e016242
pubmed: 28775188
Blood. 2017 Sep 28;130(13):1499-1506
pubmed: 28807983
Eur Urol. 2020 Jul;78(1):11-15
pubmed: 32307215
Psychooncology. 2000 May-Jun;9(3):203-13
pubmed: 10871716
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):245-248
pubmed: 32391672
BMC Med Inform Decis Mak. 2012 Nov 09;12:126
pubmed: 23140270
Bull World Health Organ. 2020 Mar 1;98(3):150
pubmed: 32132744
Transl Oncol. 2020 Feb;13(2):262-274
pubmed: 31869751
Prostate Cancer Prostatic Dis. 2020;23(3):407-409
pubmed: 32425655
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Int J Surg. 2020 Jul;79:180-188
pubmed: 32454253
Health Qual Life Outcomes. 2008 Nov 10;6:97
pubmed: 19000316
J Clin Oncol. 2003 Jan 15;21(2):374-82
pubmed: 12525532
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
Panminerva Med. 2022 Mar;64(1):72-79
pubmed: 32456404
Telemed J E Health. 2016 Apr;22(4):269-75
pubmed: 26451902